Efficacy and Safety Study of Panobinostat in Patients With Metastatic Hormone Refractory Prostate Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Confirmed diagnosis of adenocarcinoma of the prostate
Patients with metastatic hormone refractory prostate cancer
Patients that have had at least one, but not more than two prior cytotoxic treatments for prostate cancer
Evidence of disease progression by at least one of the following
two or more lesions on bone scan
progressive measurable disease
two documented increases in PSA
Willing to use contraception throughout the study and for 12 weeks after study completion
History or clinical signs of CNS disease
History of other cancers not curatively treated with no evidence of disease for more than 5 years
Prior radiotherapy within 3 weeks of starting study treatment
Prior radiopharmaceuticals (strontium, samarium)
Impaired cardiac function
Liver or renal disease with impaired function
Other protocol-defined inclusion/exclusion criteria may apply